Hepatocyte growth factor (HGF) is a potent angiogenic factor that can stimulate the production of blood vessels in ischemic tissue. We investigated whether gene therapy using HGF-expressing adenovirus could enhance skin flap survival. Sprague-Dawley rats were randomly divided into three groups. Rats were subdermally injected with HGF-expressing adenovirus (HGF virus group), recombinant HGF (rhHGF group), or phosphate buffered saline (PBS group) 2 days before and immediately after 3 × 9 cm caudal flap elevation. The survival area of the skin flap, the ratio of blood flow, CD31-positive vessels and, VEGF expression were examined. Skin flap viability was significantly increased in the HGF virus group compared to the rhHGF and PBS groups (71.4% ± 5.9%, 63.8%± 6.4%, and 39.2% ± 13.0%, respectively) (P = 0.025). Furthermore, the blood flow ratio was significantly increased in the HGF virus group. In the HGF virus group, the number of CD31-positive vessels and vascular endothelial growth factor (VEGF) expression were significantly increased. Gene therapy using HGF-expressing adenovirus increase VEGF expression, the number of viable capillaries, and blood flow to the flap, thereby improving skin flap survival. Graphical Abstract Keywords: Hepatocyte Growth Factor, Adenovirus, Gene Therapy, Skin Flap INTRODUCTION The creation of a skin flap is a simple and reproducible method for skin defect reconstruction. However, ischemic necrosis due to insufficient local blood supply is a serious complication of this procedure. Insufficient arterial blood supply and inadequate venous drainage are frequent occurrences and can result in skin flap death, especially in the distal portion where the blood flow is most likely to fail. Various surgical and non-surgical techniques have been devised to increase flap perfusion, thereby reducing the risk of ischemia. Among these, many reports have focused on increasing the local blood supply through inducing angiogenesis by means of growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), or platelet derived growth factor (PDGF) (1, 2, 3, 4, 5, 6, 7, 8). Hepatocyte growth factor (HGF) is a pleiotropic growth factor with an apparent molecular weight of 80 kDa that is capable of inducing cellular proliferation, migration, and invasiveness (9). One of the important activities of HGF is to stimulate angiogenesis of various types of cells. HGF is a potent angiogenic factor and can act on endothelial cells directly or indirectly to induce angiogenesis (10, 11, 12). Moreover, HGF stimulates the production of functional vessels in the ischemic zone by promoting the migration of vascular smooth muscle cells as well as endothelial proliferation (13). HGF has been reported to stimulate angiogenesis in rabbit, rat, and mouse ischemic hindlimb models of diabetes and high concentration lipoprotein (14, 15, 16, 17). In addition, HGF has been reported to have more potent angiogenic activity than VEGF and FGF in vitro (2). Because of its potential angiogenic benefits, several studies have investigated whether HGF can increase skin flap perfusion (18). Although skin flap neovascularization can possibly be improved by HGF, its use in a clinical setting is hampered by this protein's short half-life, poor bioavailability, and the consequent need for frequent administration to sustain long-lasting effects. For HGF to be applied clinically, an efficient drug-delivery system or alternative ways to realize the pharmacological effects of this growth factor need to be developed (19). Recent studies have shown that therapeutic angiogenesis induced by gene therapy can result in a more sustained and efficient therapeutic outcomes. Angiogenic growth factors have been evaluated in this context, and therapeutic angiogenesis using angiogenic growth factor therapy has been reported to have beneficial effects in human patients with critical limb ischemia and myocardial ischemia (2, 12, 20, 21). Of the various gene delivery systems developed for therapeutic angiogenesis, adenoviruses have been widely used because of their ability to transfer relatively large genes. Therapeutic angiogenesis by gene delivery has been used to enhance the survival of skin flaps. Inadequate perfusion, which is the most common cause of distal flap necrosis, could potentially be avoided by administering HGF to the skin flap. We therefore developed an HGF-expressing adenovirus and introduced this adenovirus into ischemic skin flaps to investigate the ability of subdermal HGF-expressing adenovirus gene therapy to augment blood perfusion and flap survival in a rat skin flap model.